Sci Transl Med：daclizumab调控调节性T细胞促进肿瘤免疫治疗 – 生物谷 (新闻发布)
生物谷 (新闻发布)Sci Transl Med：daclizumab调控调节性T细胞促进肿瘤免疫治疗生物谷 (新闻发布)由于Tregs 细胞表面表达CD25，Rech等人认为针对CD25的单抗免疫抑制药物daclizumab也许可以清除Tregs 细胞
FDA-approved Drug Makes Established Cancer Vaccine Work Better, Penn Study Finds – Penn: Office of University Communications
FDA-approved Drug Makes Established Cancer Vaccine Work Better, Penn Study FindsPenn: Office of University CommunicationsA team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania fou…
Spectrum Pharma Begins Phase 2 Study Of ZEVALIN Injection – Quick Facts – RTT News
Spectrum Pharma Begins Phase 2 Study Of ZEVALIN Injection – Quick FactsRTT News(RTTNews) – Spectrum Pharmaceuticals (SPPI: News ) announced the initiation of a Phase 2 study evaluating ZEVALIN Injection for intravenous use + rituximab in combination wi…
Remédio usado pós-transplante faz vacina contra câncer ser mais eficaz – Globo.com
Remédio usado pós-transplante faz vacina contra câncer ser mais eficazGlobo.com
Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN(R) in Combination … – MarketWatch (press release)
Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN(R) in Combination …MarketWatch (press release)The trial is designed to enroll a total of 100 patients in North America, who will be randomized to one of two treatment arms: ZEVALIN + rituxim…
MorphoSys to Present MOR208 Preclinical Combination Therapy Data at ASCO Meeting – Reuters
MorphoSys to Present MOR208 Preclinical Combination Therapy Data at ASCO MeetingReutersSynergistic Effects Seen with Four Approved Treatment Options Including Rituximab and Ofatumumab MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announ…
Combination of daclizumab and vaccine improves survival of breast cancer patients – News-Medical.net
Combination of daclizumab and vaccine improves survival of breast cancer patientsNews-Medical.netA team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved…
Is Dose-Dense Therapy Effective Against DLBCL in the Era of Rituximab? – Cancer Network
Is Dose-Dense Therapy Effective Against DLBCL in the Era of Rituximab?Cancer NetworkThe authors asked whether there is still debate surrounding dose intensity since the introduction of the monoclonal antibody rituximab (Rituxan [R]), which has improved…
Viropro, Inc. to Unlock Value from its Biosimilars Portfolio – Genetic Engineering News (press release)
Viropro, Inc. to Unlock Value from its Biosimilars PortfolioGenetic Engineering News (press release)It is from this portfolio that Viropro signed a Letter of Agreement with Spectrum Pharmaceuticals, Inc. for Rituximab, and is in active discussions with…
Viropro, Inc. to Unlock Value from its Biosimilars Portfolio – MarketWatch (press release)
Viropro, Inc. to Unlock Value from its Biosimilars PortfolioMarketWatch (press release)The starting line-up and portfolio consists of sophisticated biosimilar molecules such as Ranibizumab (biosimilar of Lucentis(R)), Trastuzumab (-Herceptin(R)), Ritux…